• Lutte contre les cancers

  • Observation

Familial risk of early and late onset cancer: nationwide prospective cohort study

Menée sur une cohorte suédoise comportant plus de 12 millions de participants (dont plus de 1 million de cas de cancer primitif), cette étude prospective évalue le risque de développer un cancer de type familial en fonction de l'âge au diagnostic du parent atteint et de la localisation de la maladie

Objective : To determine whether familial risk of cancer is limited to early onset cases. Design : Nationwide prospective cohort study. Setting : Nationwide Swedish Family-Cancer Database. Participants : All Swedes born after 1931 and their biological parents, totalling >12.2 million individuals, including >1.1 million cases of first primary cancer. Main outcome measures Familial risks of the concordant cancers by age at diagnosis. Results The highest familial risk was seen for offspring whose parents were diagnosed at an early age. Familial risks were significantly increased for colorectal, lung, breast, prostate, and urinary bladder cancer and melanoma, skin squamous cell carcinoma, and non-Hodgkin’s lymphoma, even when parents were diagnosed at age 70-79 or 80-89. When parents were diagnosed at more advanced ages (≥90), the risk of concordant cancer in offspring was still significantly increased for skin squamous cell carcinoma (hazard ratio 1.9, 95% confidence interval 1.4 to 2.7), colorectal (1.6, 1.2 to 2.0), breast (1.3, 1.0 to 1.6), and prostate cancer (1.3, 1.1 to 1.6). For offspring with a cancer diagnosed at ages 60-76 whose parents were affected at age <50, familial risks were not significantly increased for nearly all cancers. Conclusion Though the highest familial risks of cancer are seen in offspring whose parents received a diagnosis of a concordant cancer at earlier ages, increased risks exist even in cancers of advanced ages. Familial cancers might not be early onset in people whose family members were affected at older ages and so familial cancers might have distinct early and late onset components.

BMJ

Voir le bulletin